Huntley rates the stock as accumulate again this week @36 cents.
Overview
The US office with the UK and Australian offices provides access into every regional time zone. CCE now has a base to 33 countries. The strategy for the US market is slightly different with a number of strategic agents in each state. This strategy provides greater product control and enables the direct selling of product to large accounts. Ony two employees make up the US office but may change once FDA approved.
CCE invested capital is not pushed into development and research cost but into commercialisation. It is slowly building up cash flows so risk is a lot less.
This will translate to rapidly growing cash flow and hence maintain coverage with an accumulate/spec buy rating.
This is only an overview as Huntleys report was considerably more detailed. Well worth the purchase.
CCE Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
